InflaRx N.V.
IF0.DE
Deutsche Börse2.94
EUR
- -
- -
InflaRx N.V.
IF0.DE
(Deutsche Börse)
Recent
price
2.94
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- InflaRx N.V. is a clinical-stage biopharmaceutical company headquartered in Jena, Germany, specializing in the discovery and development of inhibitors targeting the complement factor C5a and its receptor C5aR. The company's core products include vilobelimab (also known as IFX-1), a first-in-class intravenously delivered anti-C5a monoclonal antibody that recently completed Phase III clinical trials for hidradenitis suppurativa, a rare chronic inflammatory skin disease, and is under clinical investigation for several other autoimmune and inflammatory disorders including anti-neutrophil cytoplasmic antibody-associated vasculitis and pyoderma gangrenosum. InflaRx is also advancing INF904, an oral small molecule inhibitor of the C5a receptor in clinical development for chronic spontaneous urticaria and hidradenitis suppurativa, and has a preclinical candidate, IFX002, aimed at treating chronic inflammation and autoimmune diseases. The company operates mainly in Germany and the United States, targeting patients with life-threatening or debilitating inflammatory conditions. Recent major developments include a successful Phase 2a clinical trial for INF904, with promising data expected to drive further value in this oral therapeutic program. InflaRx maintains a co-development and manufacturing partnership with Beijing Defengrei Biotechnology Co. Ltd., permitting the use of vilobelimab cell lines for the development of related anti-C5a antibodies in China, including the marketed product BDB-001. Financially, InflaRx conducted several public offerings in 2025, including a $30 million public offering in February and a prior $16.5 million public offering, to fund ongoing clinical development activities. The company emphasizes strategic expansion through collaborations and continues to evaluate additional indications for its pipeline products within the inflammatory and autoimmune disease markets. Founded in 2007 and formerly known as Fireman B.V. until its rebranding to InflaRx N.V. in 2017, the company focuses on complement inhibitor technology as its foundation for precision immunology therapeutics development. Its pipeline concentrates primarily on developing first-in-class and novel treatments for rare and severe inflammatory conditions, leveraging proprietary monoclonal antibodies and small molecule inhibitors. InflaRx operates offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA, serving global clinical and commercial markets in the pharmaceutical and biotechnology sectors. Its leadership team includes CEO Prof. Dr. Niels C. Riedemann, with extensive expertise in complement system biology and drug development.